Paladin will commercialize the product that is indicated for topical treatment of fingernail and toenail fungal infections (onychomycosis) in Canada with the expected launch in the latter half of 2013.
Moberg Derma president and CEO Peter Wolpert said, "Emtrix is already established as a leading product in the US and many other markets. The launch in Canada constitutes an important step in the global commercialization of Emtrix."
The Health Canada approved Emtrix works through a rapid mode of action to generate visible improvements within two to four weeks of the commencement of treatment.
Paladin Labs interim president and CEO Mark Beaudet said, "Emtrix is unique because it provides a fast and effective solution to treat nail fungus without the need for a prescription."
Financial terms of the deal were not revealed.